Keeping Track: US FDA Okays BMS’ Zeposia In MS, Nixes Lilly/BI’s Empagliflozin For Type 1 Diabetes

 
• By Bridget Silverman
Keeping Track Feature image

More from US FDA Performance Tracker

More from Regulatory Trackers